190 related articles for article (PubMed ID: 26352004)
21. Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.
Zhu F; Li X; Chen S; Zeng Q; Zhao Y; Luo F
Med Oncol; 2016 Feb; 33(2):17. PubMed ID: 26781124
[TBL] [Abstract][Full Text] [Related]
22. [The expression and clinopathological significance of miR-130b in human hepatocellular carcinoma].
Xu Q; Cai W; Zhang M; Liu Q; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):387-92. PubMed ID: 26927562
[TBL] [Abstract][Full Text] [Related]
23. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages.
Yan W; Liu X; Ma H; Zhang H; Song X; Gao L; Liang X; Ma C
Gut; 2015 Oct; 64(10):1593-604. PubMed ID: 25608525
[TBL] [Abstract][Full Text] [Related]
24. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
25. 7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma.
Yin S; Qiu Y; Jin C; Wang R; Wu S; Liu H; Koo S; Han L; Zhang Y; Gao X; Pang X; Wang T; Yu H
Int J Cancer; 2019 Dec; 145(12):3334-3346. PubMed ID: 31081930
[TBL] [Abstract][Full Text] [Related]
26. I
Wu L; Sun B; Lin X; Liu C; Qian H; Chen L; Yang Y; Shen F; Su C
Genes Cells; 2018 Jan; 23(1):35-45. PubMed ID: 29210217
[TBL] [Abstract][Full Text] [Related]
27. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
28. Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth.
Yang WL; Wei L; Huang WQ; Li R; Shen WY; Liu JY; Xu JM; Li B; Qin Y
Oncol Rep; 2014 May; 31(5):2328-34. PubMed ID: 24676454
[TBL] [Abstract][Full Text] [Related]
29. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.
Liu L; Zhu XD; Wang WQ; Shen Y; Qin Y; Ren ZG; Sun HC; Tang ZY
Clin Cancer Res; 2010 May; 16(10):2740-50. PubMed ID: 20460486
[TBL] [Abstract][Full Text] [Related]
30. [Changes of metastatic potential of residual hepatocellular carcinoma in nude mice after in vivo chemotherapy and the corresponding mechanisms].
Xiong W; Tang ZY; Ren ZG; Zhu XD; Liu L; Zhang W; Wang WQ
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):805-9. PubMed ID: 23291126
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
32. Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.
Ma JL; Zeng S; Zhang Y; Deng GL; Shen H
Tumour Biol; 2016 May; 37(5):6177-84. PubMed ID: 26614432
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization.
Ye Y; Xu Y; Lai Y; He W; Li Y; Wang R; Luo X; Chen R; Chen T
J Cell Biochem; 2018 Mar; 119(3):2951-2963. PubMed ID: 29131381
[TBL] [Abstract][Full Text] [Related]
34. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression.
Duan M; Wang ZC; Wang XY; Shi JY; Yang LX; Ding ZB; Gao Q; Zhou J; Fan J
Ann Surg Oncol; 2015 Sep; 22(9):3121-9. PubMed ID: 25465376
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
36. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
37. Osthole inhibits the tumorigenesis of hepatocellular carcinoma cells.
Lin ZK; Liu J; Jiang GQ; Tan G; Gong P; Luo HF; Li HM; Du J; Ning Z; Xin Y; Wang ZY
Oncol Rep; 2017 Mar; 37(3):1611-1618. PubMed ID: 28184928
[TBL] [Abstract][Full Text] [Related]
38. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
39. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
40. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.
Hu WH; Hu Z; Shen X; Dong LY; Zhou WZ; Yu XX
Exp Mol Pathol; 2016 Feb; 100(1):101-8. PubMed ID: 26475622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
